Tracers / [18F]AlF-NOTA-T140
[18F]AlF-NOTA-T140
Also written as [F-18]AlF-NOTA-T140
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- —
- Target / mechanism
- CXCR4 (chemokine receptor 4) PMID 39659571
- Clinical application
- PET/CT imaging of CXCR4 expression for distinguishing aldosterone-producing adenoma from other causes of primary aldosteronism PMID 39659571
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| AllinOne (AiO) Trasis | — | SPE | — | >99% | NOTA-T140 | 39659571 2024 Theranostics An AllinOne module (Trasis, Ans, Belgium) was used and modified. |
Need this precursor?We can point you to suppliers for [18F]AlF-NOTA-T140, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39659571. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 28: added indication(s) end-adrenal from consolidated missing-rubric review.